Price Band fixed at ₹ 1,265 per equity share to ₹ 1,329 per equity share of the face value of ₹ 1 each (“Equity Shares”) of Inventurus Knowledge Solutions Limited (the “Company”)
Anchor Investor Bidding Date – Wednesday, December 11, 2024
Bid /Offer Opening Date – Thursday, December 12, 2024, and Bid/ Offer Closing Date – Monday, December 16, 2024
Bids can be made for a minimum of 11 Equity Shares and in multiples of 11 Equity Shares thereafter
RHP Link: https://ikshealth.com/ir/IWA7-RHP.pdf
National, December 09, 2024(TGN): Inventurus Knowledge Solutions Limited (the “Company”) proposes to open an initial public offering of Equity Shares (“Offer”) on Thursday, December 12, 2024. The Anchor Investor Bidding Date is one working day prior to bid/offer opening date, being Wednesday, December 11, 2024. The Bid/ Offer Closing Date is Monday, December 16, 2024
The Price Band of the Offer has been fixed from ₹ 1,265 per Equity Share to ₹ 1,329 per Equity Share. Bids can be made for a minimum of 11 Equity Shares and multiples of 11 Equity Shares thereafter.
The Offer comprises of an offer for sale of up to 18,795,510 equity shares of face value of ₹ 1 each of Inventurus Knowledge Solutions Limited. The offer for sale comprising up to 1,119,300 equity shares by Aryaman Jhunjhunwala Discretionary Trust, up to up to 1,119,300 equity shares by Aryavir Jhunjhunwala Discretionary Trust, up to 1,119,300 equity shares by Nishtha Jhunjhunwala Discretionary Trust (“Promoter Selling Shareholders”), up to 3,376,311 equity shares by Ashra Family Trust, up to 26,513 equity shares by Rajeshkumar Radheshyam Jhunjhunwala, (“Promoter Group Selling Shareholders”), up to 98,250 equity shares by Adheet Sharad Gogate, up to 139,042 equity shares by Ajay Madhavan Madatiparambil, upto 72,051 equity shares by Ajit Rajagopal Menon, upto 104,281 equity shares by Alan, up to 69,521 equity shares by Ankur Chugh, up to 323,572 equity shares by Anurag Shiamsunderlal Sharma, up to 49,126 equity shares by Arindrajit Datta, up to 83,425 equity shares of by Ashit Kalra, up to 676,549 equity shares by Berjis Minoo Desai, up to 5,297 equity shares by Charles Edward Brown, up to 101,799 equity shares by Christopher J Sclafani, up to 47,035 equity shares by Clarence Carleton King Ii, up to 33,406 equity shares by Gaurav Jain, up to 1,251,378 equity shares by Gautam Char, Up to 1,141,001 equity shares by Jeffrey Philip Freimark, up to 86,901 equity shares by John Benardello, up to 3,041,812 equity shares by Joseph Benardello, up to 232,341 equity shares by K C Nishil Kumar, up to 49,126 equity shares by Kareen Ribeiro Majmudar, up to 266,781 equity shares by Katherine Nicole Davis, up to 130,594 equity shares by Madathiparambil Krishnan Madhavan, up to 55,617 equity shares by Manish Gupta, up to 166,850 equity shares by Manu Mahmud Parpia (Jointly Held With Lynn Manu Parpia), up to 61,290 equity shares by Mayur Pravinkant Sanghvi, up to 219,170 equity shares Mitul Dipak Thakker, up to 3,000 equity shares by Nikhil Sharma, up to 1,251,378 equity shares by Parminder Bolina, up to 257,873 equity shares by Patrick Burton Cline, up to 47,815 equity shares by Sanjiv Bhupendra Gandhi, up to 652,008 equity shares by Scott D Hayworth, up to 994,233 equity shares by Shane Hsuing Peng, up to 15,000 equity shares by Srikanth Vadakapurapu, up to 208,563 equity shares by Unnikrishnan Parthasarathy, up to 34,760 equity shares by Varadharajan Ramasamy and up to 63,941 equity shares by Vikram Jit Singh Chhatwal, (The “Individual Selling Shareholders”, together with the Promoter Selling Shareholders And Promoter Group Selling Shareholders, The “Selling Shareholders”) (The “Offer For Sale” Or The “Offer”)
The offer includes a reservation of up to 65,000 equity shares of face value ₹ 1 each, aggregating up to ₹[●] million, for subscription by eligible employees not exceeding 5% of our post-offer paid-up equity share capital (the “employee reservation portion”). The offer less the employee reservation portion is hereinafter referred to as the “net offer”. The offer and the net offer shall constitute [●]% and [●]%, respectively, of the fully diluted post-offer paid-up equity share capital of our company.
The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the “SCRR”), read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in accordance with Regulation 6(2) of the SEBI ICDR Regulations wherein not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors and the basis of such allocation will be on a discretionary basis by the Company, in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations (the “Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors (“Anchor Investor Allocation Price”). Further, 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis only to Mutual Funds, subject to valid Bids being received at or above the Offer Price, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not more than 15% of the Net Offer shall be available for allocation to Non Institutional Investors (“Non-Institutional Category”) of which one-third of the Non-Institutional Category shall be available for allocation to Bidders with an application size between ₹ 0.20 million to ₹ 1.00 million and two-thirds of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than Rs. 1.00 million and under-subscription in either of these two sub-categories of Non-Institutional Category may be allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Net Offer shall be available for allocation to Retail Individual Investors (“Retail Category”), in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount (“ASBA”) process and shall provide details of their respective bank account (including UPI ID for UPI Bidders using UPI Mechanism) in which the Bid Amount will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or the Sponsor Bank, as the case may be. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process
The Equity Shares of the Company are proposed to be listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”, together with BSE, the “Stock Exchanges”).
ICICI Securities Limited, Jefferies India Private Limited, JM Financial Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory and Securities (India) Private Limited are the Book Running Lead Managers to the issue.
Inventurus Knowledge Solutions Limited is a technology-enabled healthcare solutions provider. The company offers a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. They offer a comprehensive platform that enables healthcare enterprises across outpatient and inpatient care. They are a leading partner for outpatient and inpatient care organizations. They enable healthcare organizations to deliver superior clinical care, improve population health outcomes, and transition to the “fee for value” model while optimizing their revenue and reducing operating costs.
